Introduction
============

Endometriosis is characterized by the presence of endometrial tissue (glandular and stromal) abnormally outside the uterine cavity ([@b1-br-0-0-902]). According to certain statistics, there is an average of 10.4 years elapse from the first onset of symptoms to diagnosis, and 74% of patients receive at least one false diagnosis, which results in economic costs comparable with certain serious chronic diseases ([@b2-br-0-0-902]). Despite its significant impact on the quality of life and financial burden on patients, the etiology and pathophysiology of endometriosis remain unclear. Various theories have been proposed to explain the pathogenesis; however, none have interpreted it comprehensively ([@b3-br-0-0-902]). Sampson\'s retrograde menstruation theory is the most widely accepted, which proposes that fragments of the eutopic endometrium are implanted into the peritoneum or pelvic organs during menstruation through reflux via the fallopian tubes ([@b4-br-0-0-902]). Subsequently, extensive studies have been conducted to identify the differences between the eutopic and normal endometrium; indeed, various studies have demonstrated a distinct expression pattern in the eutopic endometrium compared with the normal endometrium, but the evidence is insufficient ([@b5-br-0-0-902]). In addition, laparoscopy remains the gold standard for the diagnosis of endometriosis and, to date, a histological examination is necessary for confirmation. However, this diagnostic method is a surgically invasive inspection requiring general anesthesia, which carries surgery-associated risks, such as hemorrhage, infection and adhesion formation, and requires an experienced surgeon ([@b6-br-0-0-902]). As a result of these drawbacks, non-invasive biomarkers using serum, urine and endometrial tissue as research samples have emerged; however, these current diagnostic tests for endometriosis lack sensitivity and specificity, and are difficult to repeat ([@b7-br-0-0-902]). Therefore, a thorough and comprehensive description of molecular differences between the eutopic endometrium in a patient with endometriosis and a control subject with a normal endometrium is essential to understand the pathogenesis of this disorder, and identify sensitivity and specificity biomarkers.

In the current study, it was hypothesized that the eutopic endometrium in endometriosis patients contains aberrant expression genes and exhibits dysregulated pathways that predispose itself to implant, invade and migrate outside the uterus. Messenger RNA (mRNA) sequencing was performed to detect the transcriptome expression profiling of eutopic endometrium in women with endometriosis compared with normal endometrium from healthy control subjects. Through global mRNA expression profiling, the aim was to identify candidate pathogenic genes and pathways that are implicated in the pathogenesis of endometriosis, as well as potential biomarkers of this common, clinically significant, but complex disorder.

Materials and methods
=====================

### Ethics statement

The study protocol was approved by the Local Ethics Committee of Chinese People\'s Liberation Army (PLA) General Hospital (Beijing, China), and each patient was involved in the study after providing written informed consent.

### Patient samples

Twenty-three eutopic endometria from patients with endometriosis were obtained from the Chinese PLA General Hospital between February and September 2016. Among them, eight eutopic endometria were randomly selected and prepared for mRNA sequencing (mRNA-seq), and the remaining 15 samples were used for validation. All patients were confirmed to have endometriosis by histological examination and diagnosed as being of moderate to severe stage (stage III--IV) according to the revised American Fertility Society (rAFS) classification ([@b8-br-0-0-902]) during laparoscopic surgery. None of the patients received hormone therapy prior to sampling. Twenty women without endometriosis, who underwent laparoscopic surgery for examination or hydrotubation, were included in the control group. Five endometria were randomly selected for sequencing analysis and 15 endometria were used for validation. Regions potentially exhibiting endometriotic lesions were confirmed as being negative by biopsy.

The eutopic and normal endometria were obtained via curettage prior to the laparoscopic procedure. Only patients in the secretory phase of the menstrual cycle, which was confirmed by the method of Noyes *et al* ([@b9-br-0-0-902]) were included in the study. There were no significant differences between the ages and body mass index values of the patient and control groups.

### Tissue processing, RNA extraction and quality control

All tissue samples were divided into two parts: One-half was fixed and prepared for pathological examination to identify the endometrial phase of the menstrual cycle and the other half was placed in RNAlater solution (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at 4°C for 24 h, and subsequently transferred to −80°C until use. Total RNA was extracted using the single-step acid guanidinium thiocyanate-phenol-chloroform method ([@b10-br-0-0-902]). The quality and purity of RNA were examined using a Nanodrop 8000 spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and Bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA, USA). Samples with RNA integrity number ≥8 were included.

### mRNA sequencing and data analysis

Three micrograms of RNA per sample was prepared for library construction. The Ribo-Zero Gold kit (Epicentre; Illumina, Inc., San Diego, CA, USA) and NEB Next Ultra RNA Library Prep kit (New England BioLabs, Inc., Ipswich, MA, USA) were used for rRNA removal and library construction according to the manufacturer\'s instructions. For high-throughput sequencing, paired-end 150-bp sequencing of the cDNAs was performed using the Illumina HiSeq4000 system (Illumina, Inc.), which was conducted by Annoroad Genomics (Beijing, China). Raw data were processed with Perl scripts to ensure the quality of data used for further analysis. Bowtie2 (v2.2.3; <https://sourceforge.net/projects/bowtie-bio/files/bowtie2/>) was used for building the genome index, and clean data was mapped to the human genome build (hg19) using Tophat (v2.0.12; <https://tophat.cbcb.umd.edu/>). Read counts of each gene were counted by HTSeq (v0.6.0; <http://www-huber.embl.de/users/anders/HTSeq/doc/overview.html>), and reads per kb of a gene per million reads (RPKM) were subsequently calculated to estimate the expression level of genes in each sample. DEGseq (v1.18.0; <http://www.bioconductor.org/packages/release/bioc/html/DEGseq.html>) was used for analyzing differentially expressed genes (DEGs) with the following parameters: False discovery rate (FDR) ≤0.05 and fold-change (FC) ≥2 or ≤0.5.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Five mRNAs, including matrix metallopeptidase 11 (MMP-11; ENSG00000099953), dual specificity phosphatase 1 (DUSP1; ENSG00000120129), Fos proto-oncogene, AP-1 transcription factor subunit (FOS; ENSG00000170345), serpin family E member 1 (SERPINE1; ENSG00000106366), and adenosine deaminase 2 (ADA2; ENSG00000093072) were selected for validation analysis, and GAPDH served as an mRNA endogenous control. The primers are presented in [Table I](#tI-br-0-0-902){ref-type="table"}. cDNA synthesis was conducted using a RevertAid™ First Strand cDNA Synthesis kit (Thermo Fisher Scientific, Inc.). The relative mRNA expression was determined by RT-qPCR according to the THUNDERBIRD™ SYBR qPCR Mix (Toyobo, Co., Ltd., Osaka, Japan). qRT-PCR was performed on an ABI PRISM 7500 (Applied Biosystems; Thermo Fisher Scientific, Inc.). The relative gene expression was calculated using ABI PRISM 7500 version 2.0.6 software (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the 2^−ΔΔC^q method ([@b11-br-0-0-902]).

### Functional analysis

To exploit the functional roles of DEGs, DAVID (<https://david.ncifcrf.gov/home.jsp>) was used, which integrated the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases to analyze biological function. Finally, the enrichment values of the GO terms, obtained using the hypergeometric test, were considered significantly enriched when the q-value (adjusted as a P-value) was 0.05.

Results
=======

### mRNA filtering and mapping

mRNA sequencing generated 1,396,127,582 reads, with an average of 107,204,492 reads per sample in the eutopic endometrium group and 107,698,330 reads per sample in the normal endometrium group. A fastQC quality test demonstrated that 1,374,958,606 (98.48%) reads had a Q-score ≥30, and thus were considered for further analyses. Of these reads, 93.71% were mapped to the hg19 and 98.61% were uniquely aligned. The detailed filtering and mapping data are presented in [Table II](#tII-br-0-0-902){ref-type="table"}.

### Identification of DEGs and RT-qPCR findings

Among the 13 samples, there were 40,576 mRNAs with an RPKM value of 1 in at least one sample. The transcriptome expression profiling of eutopic endometria and normal endometria exhibited very similar expression levels in the evaluated mRNAs, which directly indicated the homology of the two sequenced groups ([Fig. 1A](#f1-br-0-0-902){ref-type="fig"}). On the basis of the above-mentioned criteria of DEGs, 72 DEGs were identified with 66 upregulated genes and 6 downregulated genes ([Table III](#tIII-br-0-0-902){ref-type="table"} and [Fig. 1B](#f1-br-0-0-902){ref-type="fig"}).

Two DEGs, ADA2 and MMP-11, were significantly different in the current study, but were not previously selected for further validation. FOS, which exhibited contradictory results in previous studies, was selected. In addition, two DEGs, SERPINE1 and DUSP1, which have been associated with endometriosis in cell lines and animal models, but have not been reported in human tissue, were simultaneously selected. Although the counts of DEGs in mRNA sequencing were relatively low in the two groups, the RT-qPCR analysis indicated easily detectable expression levels. Data analysis indicated that the results from RT-qPCR were consistent with the mRNA sequencing data ([Fig. 2](#f2-br-0-0-902){ref-type="fig"}).

### Functional analysis

To gain an overall understanding of the functional roles in these DEGs, GO term and KEGG pathway analysis were conducted. The results revealed that significantly enriched GO terms under the cellular component (CC) category were extracellular matrix (ECM; GO:0031012), proteinaceous ECM (GO:0005578) and extracellular space (GO:0005615). The molecular function (MF) category included nine enriched terms, particularly in metalloendopeptidase activity (GO:0004222), growth factor activity (GO:0008083), and RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity (GO:0000982). The biological process (BP) category contained 88 enriched terms, the top three of which were response to endogenous stimulus (GO:0009719), cellular response to endogenous stimulus (GO:0071495) and response to cyclic adenosine monophosphate (GO:0051591). In addition, certain GO terms that are commonly observed in tumor-like diseases were also significantly enriched in the current results, such as growth (GO:0040007), angiogenesis (GO:0001525) and cell migration (GO:0016477). These results are presented in [Fig. 3](#f3-br-0-0-902){ref-type="fig"} and [Table IV](#tIV-br-0-0-902){ref-type="table"}. Due to the limited number of DEGs, none of the pathways were identified to be significantly enriched in the KEGG analysis with the above-mentioned thresholds.

Discussion
==========

To date, the majority of studies that focused on the eutopic endometrium of women with endometriosis were hypothesis-based studies, which evaluated a limited number of previously susceptible genes ([@b7-br-0-0-902]). A recent systematic review from 1984 to 2010 summarized \>200 potential endometrial biomarkers in the endometrium, but did not identify a standard biomarker in a clinical study ([@b12-br-0-0-902]). In addition, various studies using a microarray-based method have identified hundreds of potential pathogenic genes and pathways; however, these studies present few overlapping results ([@b13-br-0-0-902]--[@b15-br-0-0-902]). This inconsistency may be caused by various factors, including a small number of samples, poorly defined controls, different rAFS stages, different phases of the menstrual cycle, methodology limitations, various types of endometriosis, and interference by coexistent diseases. Therefore, future studies should continue to search for the important DEGs and focus on these confounding factors. To the best of our knowledge, the current study is the first to present the genome-wide gene expression profiling of the eutopic endometrium in women with endometriosis using a transcriptome sequencing technique. Considering that the genome profiling of normal endometria demonstrated marked molecular differences between samples obtained from the proliferative and secretory phases of the menstrual cycle, only mid- and late-secretory phase endometria were investigated in the patient and control groups, which represents most closely the reflux endometrium. To avoid other confounding factors, the endometriosis patients included were restricted to those in the moderate to severe stages (stages III--IV) and only those patients with ovarian endometriosis without combined diseases were enrolled. Finally, 72 DEGs enriched in 100 functional GO terms were identified. The top enriched terms in each category were ECM (GO:0031012) in CC, metalloendopeptidase activity (GO:0004222) in MF, and cellular response to endogenous stimulus (GO:0009719) in BP. Notably, various DEGs may be candidates for potential biomarkers in the eutopic endometrium of women with endometriosis.

It has been reported that human endometrium undergoes cyclic tissue remodeling during the menstrual period, during which several MMPs and ECM-associated proteins are activated ([@b16-br-0-0-902]). These proteins are suggested to facilitate the degradation and invasion of ECM and facilitate with the attachment of reflux endometrial tissue to the peritoneum and ovarian surface. In the current study, four MMP members, MMP-3, MMP-10, MMP-11, and MMP-27, were identified as upregulated in eutopic endometrium ([@b17-br-0-0-902]). Gilabert-Estellés *et al* ([@b18-br-0-0-902]) and Ramón *et al* ([@b19-br-0-0-902]) demonstrated that eutopic endometria from women with endometriosis have increased expression levels of MMP-3, which is consistent with the present result. Uzan *et al* ([@b20-br-0-0-902]) examined the immunohistochemical expression of MMP-11, although no difference was identified between the patient and control groups. Cominelli *et al* ([@b21-br-0-0-902]) suggested that MMP-27 is maximally expressed during the menstrual phase in the normal endometrium and no difference in ectopic versus eutopic endometria was observed; however, the authors did not compare between eutopic and normal endometria. Prior studies reported that the overexpression of SERPINE1 (also termed PAI-1) may result in the impairment of the fibrinolytic system, rendering the woman prone to endometriosis ([@b22-br-0-0-902]). Braza-Boïls *et al* ([@b23-br-0-0-902]) demonstrated that the protein expression levels of SERPINE1 were significantly higher in endometriotic lesions than in control endometrial tissue samples, but identified no difference between eutopic and control endometria. Unlike other members mentioned above, MMP-10, epiphycan, latent transforming growth factor β binding protein 2, cysteine rich angiogenic inducer 61, left-right determination factor 2, ADAM metallopeptidase with thrombospondin type 1 motif 16, and AP000349.2 have received little attention in endometriosis research and therefore require further confirmation.

The FOS gene family comprises four members, namely FOS, FosB proto-oncogene, AP-1 transcription factor subunit (FOSB), FOS like 1, AP-1 transcription factor subunit (FOSL1) and FOSL2. Their encoded proteins dimerize with the Jun family members to form the group of AP-1 proteins, and are involved in various physiological and pathological processes, such as cell proliferation, apoptosis, and differentiation and transformation ([@b24-br-0-0-902]). In the present study, abnormally high expression levels of FOS, FOSB, and FOSL1 were observed in eutopic endometria from patients with endometriosis, which were predominantly enriched in response to endogenous stimulus terms, nucleic acid-binding transcription factor activity terms, and response to hormone stimulus terms. FOS, as an early response gene, is critical in estrogen-mediated proliferation of endometrial cells ([@b25-br-0-0-902]). Pan *et al* ([@b26-br-0-0-902]) reported that FOS protein expression levels in eutopic and ectopic endometria samples from females with endometriosis were significantly higher than those in the endometria samples from healthy control subjects; however, the findings of Morsch *et al* ([@b27-br-0-0-902]) were not similar. Therefore, the FOS gene was selected to validate RT-qPCR in the present study, and the result was consistent with the results of Pan *et al* ([@b26-br-0-0-902]). To the best of our knowledge, the association between FOSB and FOSL1, and endometriosis have not yet been reported. As with FOS, the early growth response (EGR) family of transcription regulatory factors was predicted to be key in cellular growth and differentiation ([@b28-br-0-0-902]). Three members, EGR1, EGR2 and EGR3 were identified to be highly expressed by sequencing, which were also significantly enriched in response to endogenous stimulus terms, response to gonadotropin stimulus terms, and growth terms. Birt *et al* ([@b29-br-0-0-902]) reported the overexpression of EGR1 in endometriotic animal models and inferred that EGR1 may affect downstream protease pathways impeding ovulation in endometriosis. The roles of EGR1and EGR3 in angiogenesis has also recently been recognized and were considered to regulate certain important angiogenic factors, such as vascular endothelial growth factor A (VEGFA), fibroblast growth factor 2, and C-X-C motif chemokine ligand 1. Angiogenesis is considered to be pivotal to the implant and growth of endometriotic lesions in the pelvic microenvironment ([@b30-br-0-0-902]). The endometrium, which contains robust stem cell populations and striking regenerative ability, is a rich source of angiogenic factors ([@b31-br-0-0-902]). In the present study, enriched angiogenesis and blood vessel development terms were also observed. Aberrant upregulation of VEGFA in eutopic endometria demonstrated concordance with two earlier results: Taylor *et al* ([@b32-br-0-0-902]) emphasized the importance of VEGFA in the endometrium of women with endometriosis, as it may be activated by inflammatory-, oxidative-, hormonal- and endoplasmic reticulum-stress signals. Bourlev *et al* ([@b33-br-0-0-902]) reported a high expression level of VEGFA in the eutopic endometrium of women with endometriosis, as well as high concentrations of VEGFA in the peritoneal fluid. In addition, dysregulation of various angiogenic factors, including regulator of cell cycle, TNF receptor superfamily member 12A, nuclear receptor subfamily 4 group A member 1, epiregulin, cysteine rich angiogenic inducer 61, and S100 calcium binding protein A7, was observed in the present study in women with endometriosis when compared with those without endometriosis. Although these preliminary data require further characterization, the current findings provide novel information for future experimental studies.

In addition to gaining an improved understanding of pathogenesis, the present study attempted to identify various potential biomarkers. Although certain studies have questioned the unpleasant sensation of endometrial biopsy, the majority of participants are willing to undergo the procedure ([@b34-br-0-0-902]). In the current study, elevated expression levels of ADA2, MMP-11, FOS, SERPINE1, and DUSP1 in women with endometriosis were revealed by mRNA sequencing and RT-qPCR and, thus, these genes were considered as candidate biomarkers. Due to the limited sample size, the sensitivity, specificity, and receiver operating characteristic curve analysis were not calculated for a diagnostic test of endometriosis, which would be vital for a large sample-size study in future.

Despite the novel results, there were limitations of the current study. The primary limitation of the study is the relatively small sample size. In addition, it is difficult to evaluate whether the control endometria are from completely healthy women, as \~6% of endometriotic lesions are only visible under a microscope, and these women macroscopically presented a normal appearance ([@b35-br-0-0-902]). In addition, these preliminary results require validation by downstream experiments.

In conclusion, to the best of our knowledge, the current study presents the first genome-wide gene expression profile of eutopic endometria from women with endometriosis using a high-throughput sequencing technique. Seventy-two DEGs in eutopic endometria from women with endometriosis were compared with normal endometria from control subjects. GO analysis further revealed the important roles of these DEGs in the pathogenesis of endometriosis. Five genes, including MMP-11, DUSP1, FOS, SERPINE1, and ADA2 were further confirmed by RT-qPCR, and the results were consistent with the mRNA sequencing, indicating that these genes may present as novel biomarkers in the endometrium of women with endometriosis. The current study provides a comprehensive, but preliminary insight into elucidating the underlying mechanisms of this complex disorder, which merits further in-depth studies for confirmation.

The current study was funded by the National Natural Science Foundation of China (grant no. 81571411).
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###### 

Reverse transcription-quantitative polymerase chain reaction primers.

  Primer                                                  Length, bp   Sequence
  ------------------------------------------------------- ------------ -----------------------------------
  Matrix metallopeptidase 11                                93         Forward: GCTGCCTTCCAGGATGCTGAT
                                                                       Reverse: GCCTTCCAGAGCCTTCACCTT
  Dual specificity phosphatase 1                            85         Forward: GCCACCATCTGCCTTGCTTAC
                                                                       Reverse TGCTTCGCCTCTGCTTCACA
  Fos proto-oncogene, AP-1 transcription factor subunit   245          Forward: CGAGATTGCCAACCTGCTGAAG
                                                                       Reverse: CCATGCTGCTGATGCTCTTGAC
  Serpin family E member 1                                262          Forward: TTCAGGCTGACTTCACGAGT
                                                                       Reverse: CCAGATGAAGGCGTCTTTCC
  Adenosine deaminase 2                                   237          Forward: GGCTGTCATCGCAGAATCCATC
                                                                       Reverse: AGCATCAGAGCATCCAGAATGTTC

###### 

Summary of the mRNA sequencing data following filtering and mapping.

  Sample   Total raw reads   Total Q30 (%)   Total clean reads   Mapped reads   Unique map reads   MultiMap reads
  -------- ----------------- --------------- ------------------- -------------- ------------------ ----------------
  EU1      108,063,442       94.38           106,300,690           99,490,109     98,103,400       1,386,709
  EU5      115,796,574       94.93           114,245,924         108,073,952    106,633,173        1,440,779
  EU6        88,538,384      94.76             87,285,608          81,742,080     80,563,047       1,179,033
  EU7      125,048,606       94.97           123,155,952         116,419,348    114,821,450        1,597,898
  EU11     112,650,384       94.35           110,637,684         102,884,399    101,501,805        1,382,594
  EU18       89,731,074      94.42             88,482,524          83,389,862     82,191,074       1,198,788
  EU19     105,616,842       94.57           104,296,544           97,924,454     96,502,461       1,421,993
  EU21     112,190,626       94.68           110,717,296         103,453,282    102,134,657        1,318,625
  N2       119,170,846       94.89           117,104,548         109,135,053    107,668,064        1,466,989
  N8       100,224,148       95.00             98,937,330          92,856,399     91,660,813       1,195,586
  N12        95,701,846      94.50             94,451,810          88,290,492     87,035,145       1,255,347
  N16      106,411,788       94.92           104,457,624           97,033,960     95,631,762       1,402,198
  N19      116,983,022       93.76           114,885,072         107,817,828    106,214,767        1,603,061

###### 

Differentially expressed genes (n=72) in eutopic endometrium samples from women with endometriosis versus healthy control subjects.

  Gene symbol     Ensemble ID       Change          Fold-change   False discovery rate
  --------------- ----------------- --------------- ------------- ----------------------
  RP11-319E12.2   ENSG00000251459   Upregulated     120.99        2.32E-07
  IGFBP1          ENSG00000146678   Upregulated     115.01        1.79E-03
  SERPINB2        ENSG00000197632   Upregulated       72.95       1.51E-04
  FOSB            ENSG00000125740   Upregulated       66.12       2.01E-19
  EREG            ENSG00000124882   Upregulated       52.02       2.05E-09
  MMP27           ENSG00000137675   Upregulated       40.93       1.69E-04
  MMP10           ENSG00000166670   Upregulated       31.41       4.01E-04
  LEFTY2          ENSG00000143768   Upregulated       30.59       1.37E-08
  WIF1            ENSG00000156076   Upregulated       30.56       1.38E-04
  CDC20B          ENSG00000164287   Upregulated       25.21       6.06E-09
  LRRC15          ENSG00000172061   Upregulated       25.20       3.17E-24
  LINC01411       ENSG00000249306   Upregulated       24.95       7.67E-03
  RPL10P9         ENSG00000233913   Upregulated       21.83       3.10E-02
  IGKV1-12        ENSG00000243290   Upregulated       21.19       2.04E-05
  FAM159B         ENSG00000145642   Upregulated       20.34       2.34E-02
  INHBA           ENSG00000122641   Upregulated       15.33       1.19E-15
  FOXN4           ENSG00000139445   Upregulated       14.90       1.71E-02
  RGS1            ENSG00000090104   Upregulated       14.80       1.19E-15
  MMP3            ENSG00000149968   Upregulated       14.71       4.40E-02
  FOS             ENSG00000170345   Upregulated       14.54       2.55E-24
  IGHV1-2         ENSG00000211934   Upregulated       14.08       3.82E-04
  NR4A1           ENSG00000123358   Upregulated       13.80       8.80E-17
  EGR3            ENSG00000179388   Upregulated       13.24       1.19E-15
  VGFA            ENSG00000112715   Upregulated       13.10       8.07E-17
  RP11-459E5.1    ENSG00000253125   Upregulated       12.77       8.50E-06
  ARC             ENSG00000198576   Upregulated       12.72       3.82E-04
  EPYC            ENSG00000083782   Upregulated       12.28       4.50E-02
  KCNF1           ENSG00000162975   Upregulated       10.88       1.33E-02
  AREG            ENSG00000109321   Upregulated         9.49      6.67E-03
  FOSL1           ENSG00000175592   Upregulated         9.42      1.87E-08
  VGF             ENSG00000128564   Upregulated         9.14      3.29E-02
  NPTX1           ENSG00000171246   Upregulated         9.11      2.50E-02
  ATF3            ENSG00000162772   Upregulated         8.99      3.83E-08
  SERPINE1        ENSG00000106366   Upregulated         8.17      2.00E-04
  IL11            ENSG00000095752   Upregulated         7.97      7.57E-04
  IGFN1           ENSG00000163395   Upregulated         7.79      2.78E-05
  ASIC2           ENSG00000108684   Upregulated         7.40      1.31E-02
  NR4A3           ENSG00000119508   Upregulated         7.30      4.57E-06
  CRYGN           ENSG00000127377   Upregulated         7.25      9.11E-03
  AP000349.2      ENSG00000280178   Upregulated         7.07      4.06E-13
  MTUS2           ENSG00000132938   Upregulated         6.87      5.42E-03
  ZCCHC12         ENSG00000174460   Upregulated         6.82      1.05E-03
  MMP11           ENSG00000099953   Upregulated         6.77      5.21E-13
  ARSI            ENSG00000183876   Upregulated         6.46      9.06E-03
  LOC101929415    ENSG00000254254   Upregulated         5.90      4.56E-02
  RP11-613D13.8   ENSG00000244953   Upregulated         5.72      2.98E-03
  KRT17           ENSG00000128422   Upregulated         5.56      9.34E-05
  EGR1            ENSG00000120738   Upregulated         5.47      1.43E-09
  CYR61           ENSG00000142871   Upregulated         5.38      2.70E-09
  GEM             ENSG00000164949   Upregulated         4.72      7.61E-06
  C11orf96        ENSG00000187479   Upregulated         4.57      2.05E-04
  PTHLH           ENSG00000087494   Upregulated         4.51      3.73E-02
  EGR2            ENSG00000122877   Upregulated         4.41      1.33E-02
  DUSP1           ENSG00000120129   Upregulated         4.35      2.05E-04
  LOC102724428    ENSG00000275993   Upregulated         4.35      8.21E-03
  PAMR1           ENSG00000149090   Upregulated         4.23      1.34E-03
  TNFRSF12A       ENSG00000006327   Upregulated         3.83      5.70E-03
  DUSP5           ENSG00000138166   Upregulated         3.66      1.60E-03
  SLC47A1         ENSG00000142494   Upregulated         3.62      8.33E-03
  ADAMTS16        ENSG00000145536   Upregulated         3.39      1.45E-02
  CAB39L          ENSG00000102547   Upregulated         3.38      1.65E-03
  HES1            ENSG00000114315   Upregulated         3.23      6.51E-03
  HTRA3           ENSG00000170801   Upregulated         3.17      1.60E-03
  LTBP2           ENSG00000119681   Upregulated         2.92      6.92E-03
  LOC284454       ENSG00000267519   Upregulated         2.89      4.88E-02
  RGCC            ENSG00000102760   Upregulated         2.74      4.03E-02
  LRRC26          ENSG00000184709   Downregulated   109.57        2.98E-03
  S100A7          ENSG00000143556   Downregulated     40.68       5.10E-08
  PWP2            ENSG00000241945   Downregulated     18.29       8.21E-03
  GUCY1B2         ENSG00000123201   Downregulated     11.64       6.54E-03
  CTD-2384B11.2   ENSG00000225407   Downregulated       7.54      6.54E-03
  ADA2            ENSG00000093072   Downregulated       3.23      1.30E-02

###### 

Top 10 enriched GO terms of DEGs in the endometrium from women with endometriosis compared with healthy control subjects.

  Category   GO ID        Description                                                Q value    n    Involved DEGs
  ---------- ------------ ---------------------------------------------------------- ---------- ---- -----------------------------------------------------------------------------------------------------------------------------------------------
  BP         GO:0009719   Response to endogenous stimulus                            4.47E-07   21   CAB39L, SERPINE1, AREG, HES1, NR4A3, LTBP2, DUSP1, EGR1, INHBA, EGR2, NR4A1, EREG, FOSB, VGF, LEFTY2, IGFBP1, MMP3, HTRA3, FOSL1, EGR3, VEGFA
  BP         GO:0071495   Cellular response to endogenous stimulus                   1.54E-06   17   CAB39L, SERPINE1, HES1, LTBP2, DUSP1, EGR1, INHBA, EGR2, NR4A1, EREG, FOSB, LEFTY2, IGFBP1, MMP3, HTRA3, EGR3, VEGFA
  BP         GO:0051591   Response to cyclic adenosine monophosphate                 1.54E-06   8    AREG, DUSP1, EGR1, EGR2, FOSB, VGF, FOSL1, EGR3
  CC         GO:0031012   Extracellular matrix                                       4.5E-06    11   EPYC, MMP11, SERPINE1, LTBP2, MMP27, CYR61, LEFTY2, ADAMTS16, MMP3, MMP10, AP000349.2
  BP         GO:0001525   Angiogenesis                                               1.2E-05    9    TNFRSF12A, RGCC, SERPINE1, NR4A1, EREG, CYR61, S100A7, EGR3, VEGFA
  BP         GO:0046683   Response to organophosphorus                               1.49E-05   8    AREG, DUSP1, EGR1, EGR2, FOSB, VGF, FOSL1, EGR3
  BP         GO:0014074   Response to purine-containing compound                     1.95E-05   8    AREG, DUSP1, EGR1, EGR2, FOSB, VGF, FOSL1, EGR3
  BP         GO:0048646   Anatomical structure formation involved in morphogenesis   3.16E-05   17   TNFRSF12A, PTHLH, RGCC, SERPINE1, NR4A3, DUSP1, INHBA, EGR2, NR4A1, EREG, DUSP5, FOXN4, CYR61, S100A7, ADAMTS16, EGR3, VEGFA
  BP         GO:0010243   Response to organonitrogen compound                        5.42E-05   14   CAB39L, AREG, HES1, NR4A3, DUSP1, EGR1, EGR2, EREG, FOSB, VGF, IGFBP1, MMP3, FOSL1, EGR3
  BP         GO:0009725   Response to hormone stimulus                               8.50E-05   14   CAB39L, AREG, HES1, NR4A3, DUSP1, EGR1, INHBA, EGR2, EREG, FOSB, VGF, IGFBP1, FOSL1, EGR3

GO, Gene Ontology; DEG, differentially expressed gene; BP, biological process; CC, cellular component.
